TY - JOUR T1 - Response to: ‘Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’’ by Jeny <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e242 LP - e242 DO - 10.1136/annrheumdis-2020-218983 VL - 81 IS - 12 AU - Andrea Hermina Györfi AU - Georg Schett AU - Jörg H W Distler Y1 - 2022/12/01 UR - http://ard.bmj.com/content/81/12/e242.abstract N2 - We thank Cohen Aubart et al for their correspondence.1 Their study on 36 patients with sarcoidosis and COVID-19 from 15 French centres provides interesting insights on the outcome of COVID-19 in this group of patients. These data provide evidence that a higher percentage of patients with sarcoidosis with COVID-19 might require intensive care support than in the general population. In contrast, sarcoidosis does not seem to affect the severity of COVID-19, and patients with sarcoidosis-associated interstitial lung disease (ILD) are not admitted more often to the intensive care unit (ICU) than patients without ILD.The data by Cohen Aubart et al 1 show that 85% of the patients with sarcoidosis with COVID-19 admitted … ER -